US company Moderna said it would record programs Monday for emergency approval of its Covid-19 vaccine in the United States and Europe, after full effects showed an estimated maximum efficacy of 94. 1%.
“Our vaccine will provide a new and resilient tool that can replace the course of this pandemic and help you avoid serious illnesses, hospitalizations and deaths,” said the company’s CEO, Stéphane Bancel.
If the U. S. Food and Drug Administration were to do so, it would not be able to do so. But it’s not the first time He says it is safe and effective, the first of two doses of the drug can be injected into the arms of millions of Americans until mid-December.
U. S. pharmaceutical company Pfizer and Germany’s BioNTech sought similar approvals last week, and their vaccine may light up in the US. But it’s not the first time Shortly after December 10.
The Modern vaccine, which evolved together with the US National Institutes of Health, has evolved together with the US National Institutes of Health. Usa, it is being studied in a clinical trial with more than 30,000 participants in the United States.
An interim investigation announced earlier this month was based on 95 patients who have become ill with Covid-19.
The final research was based on 196 cases, of which 185 were observed in a placebo-winning organization compared to 11 who won the injections.
Modern Headquarters in Cambridge, Massachusetts – The company will register an emergency authorization application for its Covid-19 vaccine in the United States and Europe Photo: AFP / Joseph Prezioso
Thirty other people had severe cases, all in the placebo organization, which also included a deceased person.
Significantly, the effectiveness is uniform across age, race, ethnicity and gender, the company said.
The 196 instances of Covid-19 included 33 adults over the age of 65 and 42 participants known as community members (including 29 Hispanics, six blacks, 4 Asian-Americans, and 3 multiracials).
The vaccine has been well tolerated, with maximum non-unusual side effects, adding injection site pain, fatigue, muscle pain, joint pain, headache and site redness.
These are higher in frequency and severity after the dose in the vaccinated group.
The press release included the line: “No new serious protection disorders have been known through the company”; however, he explicitly indicated whether serious disorders had previously been reported.
Moderna said it expects to have about 20 million doses of the vaccine, called mRN-1273, in the United States until the end of the year.
It plans to manufacture between 500 million and one billion international doses by 2021.